Theralase Technologies (TSX:V.TLT, Stock Forum), a Toronto-based designer, developer, manufacturer and marketer of patented, super-pulsed laser technology used in clinical applications, announced today that the company's president and CEO, Roger Dumoulin-White, was interviewed by CBC's senior business correspondent and anchor, Amanda Lang, on The Lang and O'Leary Exchange.
According to the news release, the interview centred around the company and how it is breaking significant new ground in anti-cancer and pain management technology.
The company, which for the last 20 years, has designed and manufactured patented therapeutic laser technology used for the elimination of pain, reduction of inflammation and the dramatic acceleration of tissue healing, has sold over 800 systems in Canada and over 400 systems in the United States and international markets to such licensed practitioners as medical doctors, chiropractors, physical therapists and athletic therapists.
More recently, Theralase celebrated animal research results that showed its PDC technology was not only able to destroy the primary tumor, but it also revealed a “memory response” for the technology where once the primary tumor was destroyed, repeated injections of cancer cells a few weeks post-treatment, or even 10 months post-treatment, did not generate cancerous tumors and in fact, prevented the recurrence of cancer.
Roger Dumoulin-White commented on the event, “My appearance on Canada's top business program confirms that Theralase is emerging as a major research and manufacturing company in two of the most important sectors of the healthcare industry - seeking a cure for cancer and alleviating pain. It is estimated that $91 Billion is spent on the war on cancer and $100 Billion on pain in the United States, annually.”
He then added, “Our therapeutic laser technology has been clinically proven to eliminate pain, reduce inflammation and accelerate tissue repair, healing millions of patient's nerve, muscle and joint conditions, effectively.”
And then he finally concluded, “We are very excited about the possibilities for Theralase's anti-cancer technology. If it shows the same efficacy in humans that it has in animals, then our PDC anti-cancer technology and the implications of this "memory response" discovery are nothing short of game changing for both Theralase and for cancer patients.”
Theralase was in the news recently when the company announced its laser technology was used by star athletes for pain management.
Shares rose 7.94% on the news to $0.34 per share.
Currently there are 66.6m outstanding shares with a market cap of $22.6 million.
FULL DISCLOSURE: Theralase Technologies is a Stockhouse Publishing client.